Catalent, Inc. (CTLT)
| Market Cap | 10.10B |
| Revenue (ttm) | 4.10B |
| Net Income (ttm) | -1.30B |
| Shares Out | 180.97M |
| EPS (ttm) | -7.19 |
| PE Ratio | n/a |
| Forward PE | 48.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,429,830 |
| Open | 55.97 |
| Previous Close | 55.95 |
| Day's Range | 55.75 - 56.14 |
| 52-Week Range | 31.45 - 60.20 |
| Beta | 1.19 |
| Analysts | Hold |
| Price Target | 52.04 (-6.74%) |
| Earnings Date | May 7, 2024 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syring... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $52.04, which is a decrease of -6.74% from the latest price.
News
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
SAN DIEGO--(BUSINESS WIRE)---- $CTLT #CTLT--Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT).
Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a sp...
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and ...
Novo Owner's CEO on Obesity Sales Boom, Catalent Deal
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are advised to cont...
Novo Nordisk expects Catalent deal to close later this year
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is see...
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corpora...
CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (...
Wegovy packing supplier Catalent lays off 300 workers
Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday.
Catalent Q2 sales inch past estimates amid takeover by Novo Holdings
Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's paren...
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the s...
Astrazeneca says Catalent deal shows importance of in-house capacity
Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. F...
EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo
The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk , part of its mandat...
US FDA finds control lapses at Catalent plant being sold to Novo
U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, ac...
Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.
Shareholder Alert: Ademi LLP investigates whether Catalent, Inc. has obtained a Fair Price in its transaction with Novo Holdings
MILWAUKEE , Feb. 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Catalent (NYSE: CTLT) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Holdings. Cl...
SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Catalent (NYSE:CTLT) breached their fiduciary duties in conn...
CTLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Catalent, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings for $63.50 per share in cash is fair to Cata...
Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal
The controlling shareholder of Wegovy maker Novo Nordisk is buying Catalent in a deal that values the U.S. drug company at $16.5 billion, including debt.
Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk
Novo Holdings will acquire Catalent for $63.50 a share in cash.
Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity
Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss ...
Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion
Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's clos...
Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction...